Aftab Blake 4

What Happened
Aftab Blake, Chief Scientific Officer of Adicet Bio (ACET), received a grant of 72,555 derivative securities on 2026-03-25. The filing lists the acquisition price as $0.00 per share (total $0 on the Form 4), indicating an awarded equity grant rather than a market purchase or sale.

Key Details

• Transaction date: 2026-03-25; Form 4 filed 2026-03-27 (timely filing).
• Transaction type: A (award/grant) of derivative securities — 72,555 shares at $0.00 per share (reported value $0).
• Shares owned after transaction: Not disclosed in the provided filing.
• Footnote: (1) 1/48th of the shares vest on each of the next 48 monthly anniversaries of the grant date, subject to continued service.
• No indication in the filing of a 10b5-1 plan, immediate sale, tax-withholding sale, or other special instructions.

Context
This is an equity award (derivative securities) that vests monthly over four years, conditional on continued employment. Such grants are common as compensation and do not represent an open-market purchase or sale. The filing appears timely (filed two days after the transaction date).